Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin (BAY12-8039) Clear all
Completed Phase 4 Interventional

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

NCT00758199
View directory record Official record
Conditions
Cataracts
Interventions
Bromfenac, Moxifloxacin hydrochloride, Prednisolone Acetate
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

NCT05933447
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl, Moxifloxacin, Placebo for Rodatristat, Placebo for Moxifloxacin
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

NCT06441318
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

NCT03187301
View directory record Official record
Conditions
Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions
APL-130277, Placebo, Moxifloxacin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on the Electrical Activity of the Heart

NCT01537887
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793
View directory record Official record
Conditions
Healthy
Interventions
tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304
View directory record Official record
Conditions
QT/QTc Interval in Healthy Volunteers
Interventions
WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT06161220
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

NCT01941511
View directory record Official record
Conditions
Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

NCT07422298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

AMS VS MOXI Ketek vs Avelox in AMS

NCT00537563
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
Telithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

NCT06215521
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 11, 2026, 5:38 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

NCT00789568
View directory record Official record
Conditions
Phenylketonuria
Interventions
sapropterin dihydrochloride, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

NCT01775761
View directory record Official record
Conditions
TTR Cardiomyopathy
Interventions
Period 1, Period 2, Period 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

NCT01812538
View directory record Official record
Conditions
Ventricular Repolarization
Interventions
DIC075V
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699
View directory record Official record
Conditions
Pediculosis
Interventions
Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 4 Interventional

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233
View directory record Official record
Conditions
Corneal Health, Cataract Surgery
Interventions
besivance, vigamox
Drug
Lead sponsor
Ophthalmology Consultants, Ltd.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Oct 11, 2026, 5:38 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

NCT03244072
View directory record Official record
Conditions
Endophthalmitis
Interventions
Moxifloxacin, Placebo
Drug
Lead sponsor
Jason Ahee, M.D.
Industry
Eligibility
40 Years and older
Enrollment
60,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
St. George, Utah
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 11, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

NCT00434395
View directory record Official record
Conditions
Healthy
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 11, 2026, 5:38 AM EDT